GLP-1 Skincare
GLP-1 skincare is the newest label in the beauty aisle, and I saw it coming before the serums did. The story did not start with a cream. It started with a pill, a price drop, and millions of people changing how they eat. Here is the ecosystem, and where the proof stops.
GLP-1 Skincare Starts With the Pill
McKinsey’s new Future of Wellness 2027 report says GLP-1 medications became more accessible over the past year. It points to patent expirations, new oral formulations, and lower prices. Those changes are lifting categories from food and beverage to beauty and aesthetics.
The pill is the clearest marker. The FDA approved the Wegovy pill in December 2025. Novo Nordisk launched it on January 5, 2026, with a $149 monthly cash price for the starter dose. Eli Lilly’s oral option followed this spring.
GLP-1 Skincare Reach: How Many People Are Using It
KFF polling from late 2025, reported by AOL, found that 18% of US adults have ever used a GLP-1 and 12% currently do. That is the customer base behind every GLP-1 skincare launch.

GLP-1 Skincare Demand: What McKinsey Measured
McKinsey surveyed GLP-1 users about what else changed in their routines. This is the ecosystem in three numbers:
- 35% eat more protein.
- 19% added supplements.
- 18% picked up strength training.

The beauty number is the one I kept returning to. Aesthetic providers told McKinsey that 63% of GLP-1 patients seeking facial treatments had never used those services before. These are new customers, not regulars.
GLP-1 Skincare Worry: The Face Question
An Allergan Aesthetics survey of healthcare professionals, presented at the 2026 AAD meeting, estimated that 52% of GLP-1 patients worry about their facial appearance. Providers reported that 32% of these patients are new to their practice. The top barriers were cost (82%) and fear of unnatural results (58%).

GLP-1 Skincare Brands Moving In
GLP-1 Skincare From the Beauty Giants
Reuters reported on October 21 that Galderma, Natura, and L’Oréal are all testing treatments for facial sagging and volume loss in this group. L’Oréal’s innovation chief confirmed the company is running studies with GLP-1 users. Allergan Aesthetics presented two small studies in September on skincare and non-invasive treatments for people on weight-loss medications.
Natura’s innovation chief told Reuters that the answer will not be creams alone. Supplements and ingestibles are part of the thinking.
GLP-1 Skincare on the Shelf Right Now
Some brands did not wait for the giants. Launches already positioned around GLP-1 users include:
- Image Skincare’s VOL.U.LIFT GLP-1 4D Skin Rebound Complex, aimed at deflation and density loss (MDLinx)
- Few Skincare’s DermaReverse (MDLinx)
- Mblue Labs’ Fit+Firm Serum, COSRX’s Blue Peptide Bakuchiol Plump Glow Serum, and ElastiK° Skin from the Renatus Collective (AOL)
GLP-1 Skincare Claims vs. Proof
This is where I slow down. A dermatologist quoted by MDLinx describes much of GLP-1 skincare as familiar ingredients in new packaging. Such products may improve hydration, texture, and perceived firmness. They will not replace lost facial fat or rebuild structure.
The Reuters piece adds nuance. Experts say facial volume loss is tied to rapid weight loss, not to the drugs themselves. Diet quality may also play a role, and the picture is multifactorial. Galderma noted that its injectables are not approved specifically for GLP-1 users, even as it works with aesthetic providers who treat them.
GLP-1 Skincare and the Proof Gap
McKinsey’s wider finding applies here. Effectiveness now ties price as the top factor in wellness purchases. The biggest spenders rank it above price. A GLP-1 skincare label alone will not carry a product for long. Evidence will.
GLP-1 Skincare: What I’m Watching
I see three things worth watching:
- Clinical backing. Watch for brands that publish studies on GLP-1 users. Allergan and L’Oréal are already testing.
- Format shift. Expect pairings of topicals, supplements, and in-office care rather than a single cream.
- Patient growth. One aesthetics expert at an October NewBeauty roundtable estimated that GLP-1s could double the number of aesthetic patients within five years. That is one expert’s math, not a forecast.
For the bigger picture, read the Studio’s brief on the wellness takeover.
This Signal is editorial intelligence, not medical advice. Talk to a licensed clinician about GLP-1 medications and skin concerns.
GLP-1 Skincare Sources
- McKinsey & Company, Future of Wellness 2027: Inside the $2.7 trillion takeover (Nov 3, 2026)
- Reuters via U.S. News, Beauty Giants Target ‘Ozempic Face’ (Oct 21, 2026)
- Estética Export, The GLP-1 Effect (Oct 26, 2026)
- MDLinx, ‘GLP-1-branded skincare’ and other dermatology trends
- AOL, How GLP-1 Weight Loss Drugs Are Creating a New Beauty Market (Aug 10, 2026; cites KFF polling)
- Allergan Aesthetics (AbbVie) via Barchart, AAD 2026 findings (Mar 30, 2026)
- NewBeauty, State of Aesthetics Roundtable: GLP-1 Revolution (Oct 2026)
- Novo Nordisk, Wegovy pill launch release (Jan 5, 2026)
- ABC7 Los Angeles, FDA approval of the Wegovy pill (Dec 2025)